On June 24, 2024, BioNTech SE announced that the FDA granted Fast Track designation for their drug BNT324/DB-1311, aimed at treating advanced prostate cancer.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.